Bisphosphonates are widely used for the treatment of
osteoporosis and are generally well tolerated. However, the United States Food and Drug Administration safety reports have highlighted the issue of renal safety in
bisphosphonate-treated patients. All
bisphosphonates carry labeled "warnings" or a
contraindication for use in patients with severe renal impairment (
creatinine clearance <30 or <35 mL/min). Data from pivotal trials and their extension studies of
bisphosphonates approved for the management of
osteoporosis were obtained via PubMed, and were reviewed with support from published articles available on PubMed. Renal safety analyses of pivotal trials of oral
alendronate,
risedronate, and
ibandronate for
postmenopausal osteoporosis showed no short-term or long-term effects on renal function. Transient postinfusion increases in serum
creatinine have been reported in patients receiving intravenous
ibandronate and
zoledronic acid; however, studies showed that treatment with these agents did not result in long-term renal function deterioration in clinical trial patients with
osteoporosis. All
bisphosphonate therapies have "warnings" for use in patients with severe renal impairment. Clinical trial results have shown that even in elderly, frail, osteoporotic patients with renal impairment, intravenous
bisphosphonate therapy administration in accordance with the prescribing information did not result in long-term renal function decline. Physicians should follow guidelines for
bisphosphonate therapies administration at all times.